Multidrug-resistant Organisms in Military Wounds from Iraq and Afghanistan

  • Jason H. Calhoun
  • Clinton K. Murray
  • M. M. Manring
Symposium: Papers Presented at the 2007 Meeting of the Musculoskeletal Infection Society

Abstract

Mortality from battlefield wounds has historically declined, thanks to better surgical management, faster transport of casualties, and improved antibiotics. Today, one of the major challenges facing U.S. military caregivers is the presence of multidrug-resistant organisms in orthopaedic extremity wounds. The most frequently identified resistant strains of bacteria are Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter calcoaceticus-baumannii complex. Overuse of broad-spectrum antibiotics may be an important factor in building resistant strains. Acinetobacter infections appear to hospital-acquired and not from an initial colonization of the injury. More research is required to give military physicians the tools they require to reduce the infection rate and defeat multidrug-resistant organisms.

References

  1. 1.
    Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep. 2004;53:1063–1066.Google Scholar
  2. 2.
    Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, Hospenthal DR, Holcomb JB, Wolf SE. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203:546–550.PubMedCrossRefGoogle Scholar
  3. 3.
    Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Vol 2. Philadelphia, PA: Churchill Livingstone; 2000:2339–2344.Google Scholar
  4. 4.
    Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996;22:387–394.PubMedCrossRefGoogle Scholar
  5. 5.
    Barnea Y, Carmeli Y, Gur E, Kuzmenko B, Gat A, Neville LF, Eren R, Dagan S, Navon-Venezia S. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model. Plast Reconstr Surg. 2006;117:2284–2291.PubMedCrossRefGoogle Scholar
  6. 6.
    Barnea Y, Carmeli Y, Kuzmenko B, Gur E, Hammer-Munz O, Navon-Venezia S. The establishment of a Pseudomonas aeruginosa-infected burn-wound sepsis model and the effect of imipenem treatment. Ann Plast Surg. 2006;56:674–679.PubMedCrossRefGoogle Scholar
  7. 7.
    Bi L, Hu Y, Fan H, Meng G, Liu J, Li D, Lv R. Treatment of contaminated bone defects with clindamycin-reconstituted bone xenograft-composites. J Biomed Mater Res B Appl Biomater. 2007;82:418–427.PubMedGoogle Scholar
  8. 8.
    Bratzler DW. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg. 2005;140:174–182.PubMedCrossRefGoogle Scholar
  9. 9.
    Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706–1715.PubMedCrossRefGoogle Scholar
  10. 10.
    Calhoun JH, Crist BD, Della Rocca GJ, Yin LY. Modification of an Accepted Animal Model of Osteomyelitis to Simulate and Evaluate Treatment of War Extremity Wounds. Columbia, Mo.: U.S. Army Institute of Surgical Research; 2006:10–11.Google Scholar
  11. 11.
    Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11:1218–1224.PubMedGoogle Scholar
  12. 12.
    DeWaal HL. Wound infection. A preliminary note on a combined clinical and bacteriological investigation of 708 wounds. Edinburgh Med J. 1943;L:577–589.Google Scholar
  13. 13.
    Dougherty PJ, Carter PR, Seligson D, Benson DR, Purvis JM. Orthopaedic surgery advances resulting from World War II. J Bone Joint Surg Am. 2004;86:176–181.PubMedGoogle Scholar
  14. 14.
    Eastridge BJ, Jenkins D, Flaherty S, Schiller H, Holcomb JB. Trauma system development in a theater of war: experiences from Operation Iraqi Freedom and Operation Enduring Freedom. J Trauma. 2006;61:1366–1372; discussion 1372–1363.PubMedGoogle Scholar
  15. 15.
    Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–2751.PubMedCrossRefGoogle Scholar
  16. 16.
    Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego-Lara SL, Madrazo-Osuna J. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111–1118.PubMedCrossRefGoogle Scholar
  17. 17.
    Garzoni C, Emonet S, Legout L, Benedict R, Hoffmeyer P, Bernard L, Garbino J. Atypical infections in tsunami survivors. Emerg Infect Dis. 2005;11:1591–1593.PubMedGoogle Scholar
  18. 18.
    Gawande A. Casualties of war–military care for the wounded from Iraq and Afghanistan. N Engl J Med. 2004;351:2471–2475.PubMedCrossRefGoogle Scholar
  19. 19.
    Gondusky JS, Reiter MP. Protecting military convoys in Iraq: an examination of battle injuries sustained by a mechanized battalion during Operation Iraqi Freedom II. Mil Med. 2005;170:546–549.PubMedGoogle Scholar
  20. 20.
    Griffith ME, Ceremuga JM, Ellis MW, Guymon CH, Hospenthal DR, Murray CK. Acinetobacter skin colonization of US Army Soldiers. Infect Control Hosp Epidemiol. 2006;27:659–661.PubMedCrossRefGoogle Scholar
  21. 21.
    Griffith ME, Lazarus DR, Mann PB, Boger JA, Hospenthal DR, Murray CK. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol. 2007;28:720–722.PubMedCrossRefGoogle Scholar
  22. 22.
    Hardaway RM. 200 years of military surgery. Injury. 1999;30:387–397.PubMedCrossRefGoogle Scholar
  23. 23.
    Hardaway RM. Wound shock: a history of its study and treatment by military surgeons. Mil Med. 2004;169:265–269.PubMedGoogle Scholar
  24. 24.
    Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, Jorgensen JH. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother. 2007;51:376–378.PubMedCrossRefGoogle Scholar
  25. 25.
    Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146–155.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;45:409–415.PubMedCrossRefGoogle Scholar
  27. 27.
    Kanafani ZA, Kara L, Hayek S, Kanj SS. Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms. Infect Control Hosp Epidemiol. 2003;24:864–869.PubMedCrossRefGoogle Scholar
  28. 28.
    Kiehn CL. Progress attained in the search for the primary healing of gunshot wounds of the extremities in the ETO in World War II. Bull N Y Acad Med. 1989;65:866–878.PubMedGoogle Scholar
  29. 29.
    Klein RS, Berger SA, Yekutiel P. Wound infection during the Yom Kippur war: observations concerning antibiotic prophylaxis and therapy. Ann Surg. 1975;182:15–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Kovaric JJ, Matsumoto T, Dobek AS, Hamit HF. Bacterial flora of one hundred and twelve combat wounds. Mil Med. 1968;133:622–624.PubMedGoogle Scholar
  31. 31.
    Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008–1011.PubMedCrossRefGoogle Scholar
  32. 32.
    Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E, Sauaia N, Boulos M. An outbreak of multiresistant Acinetobacter baumanii in a university hospital in Sao Paulo, Brazil. Infect Control Hosp Epidemiol. 1996;17:366–368.PubMedCrossRefGoogle Scholar
  33. 33.
    Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154–160.PubMedCrossRefGoogle Scholar
  34. 34.
    Lortholary O, Fagon JY, Buu Hoi A, Mahieu G, Gutmann L. Colonization by Acinetobacter baumanii in intensive-care-unit patients. Infect Control Hosp Epidemiol. 1998;19:188–190.PubMedCrossRefGoogle Scholar
  35. 35.
    Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;111:676–685.PubMedCrossRefGoogle Scholar
  36. 36.
    Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7:R78–83.PubMedCrossRefGoogle Scholar
  37. 37.
    Mazurek MT, Ficke JR. The scope of wounds encountered in casualties from the global war on terrorism: from the battlefield to the tertiary treatment facility. J Am Acad Orthop Surg. 2006;14(10 Suppl):S18–23.PubMedGoogle Scholar
  38. 38.
    McKissock W, Wright J, Miles AA. The reduction of hospital infection of wounds. A controlled experiment. Br Med J. 1941;2:375–377.Google Scholar
  39. 39.
    Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115–121.PubMedCrossRefGoogle Scholar
  40. 40.
    Miles AA, Schwabacher H, Cunliffe AC. Hospital infection of war wounds. Br Med J. 1940;2:855–859, 895–900.Google Scholar
  41. 41.
    Murray CK, Hospenthal DR. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis. 2005;18:502–506.PubMedCrossRefGoogle Scholar
  42. 42.
    Murray CK, Roop SA, Hospenthal DR, Dooley DP, Wenner K, Hammock J, Taufen N, Gourdine E. Bacteriology of war wounds at the time of injury. Mil Med. 2006;171:826–829.PubMedGoogle Scholar
  43. 43.
    Oncul O, Keskin O, Acar HV, Kucukardali Y, Evrenkaya R, Atasoyu EM, Top C, Nalbant S, Ozkan S, Emekdas G, Cavuslu S, Us MH, Pahsa A, Gokben M. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect. 2002;51:47–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Paolino K, Erwin D, Padharia V, Carrero H, Giron L, Burgess R, Burger C, Martinez M, Arrieta P, Wortmann G, Zapor M. In vitro activity of colistin against multidrug-resistant gram-negative bacteria isolated at a major army hospital during the military campaigns in Iraq and Afghanistan. Clin Infect Dis. 2007;45:140–141.PubMedCrossRefGoogle Scholar
  45. 45.
    Pollak AN, Calhoun JH. Introduction. J Am Acad Orthop Surg. 2006;14(10 Suppl):viii–ix.PubMedGoogle Scholar
  46. 46.
    Rotimi VO, al-Sweih NA, Feteih J. The prevalence and antibiotic susceptibility pattern of gram-negative bacterial isolates in two ICUs in Saudi Arabia and Kuwait. Diagn Microbiol Infect Dis. 1998;30:53–59.PubMedCrossRefGoogle Scholar
  47. 47.
    Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: A Review 4 Years after First Approval. Pharmacology. 2007;81:79–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Schaad HJ, Bento M, Lew DP, Vaudaux P. Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. BMC Infect Dis. 2006;6:74.PubMedCrossRefGoogle Scholar
  49. 49.
    Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S, Lindler L, Mancuso J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G, Petersen K, Endy T, Petruccelli B. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007;44:1577–1584.PubMedCrossRefGoogle Scholar
  50. 50.
    Smallman-Raynor MR, Cliff AD. Impact of infectious diseases on war. Infect Dis Clin North Am. 2004;18:341–368.PubMedCrossRefGoogle Scholar
  51. 51.
    Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother. 2007;51:2540–2545.PubMedCrossRefGoogle Scholar
  52. 52.
    U.S. casualty status. U.S. Department of Defense Web site. Available at: http://www.defenselink.mil/news/casualty.pdf. Accessed 26 Nov 2007.
  53. 53.
    Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–1624.PubMedCrossRefGoogle Scholar
  54. 54.
    Vara Prasad J. New oxazolidinones. Curr Opin Microbiol. 2007 Oct;10:454–460.PubMedCrossRefGoogle Scholar
  55. 55.
    Velmahos GC, Jindal A, Chan L, Kritikos E, Vassiliu P, Berne TV, Demetriades D. Prophylactic antibiotics after severe trauma: more is not better. Int Surg. 2001;86:176–183.PubMedGoogle Scholar
  56. 56.
    Velmahos GC, Toutouzas KG, Sarkisyan G, Chan LS, Jindal A, Karaiskakis M, Katkhouda N, Berne TV, Demetriades D. Severe trauma is not an excuse for prolonged antibiotic prophylaxis. Arch Surg. 2002;137:537–541; discussion 541–532.PubMedCrossRefGoogle Scholar
  57. 57.
    Walters TJ, Mabry RL. Issues related to the use of tourniquets on the battlefield. Mil Med. 2005;170:770–775.PubMedGoogle Scholar
  58. 58.
    Wannamaker GT, Pulaski EJ. Pyogenic neurosurgical infections in Korean battle casualties. J Neurosurg. 1958;15:512–518.PubMedCrossRefGoogle Scholar
  59. 59.
    Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma. 2006;60:655–658.PubMedGoogle Scholar
  60. 60.
    Whitman TJ. Infection control challenges related to war wound infections in the ICU setting. J Trauma. 2007;62(6 Suppl):S53.PubMedGoogle Scholar
  61. 61.
    Yarboro SR, Baum EJ, Dahners LE. Locally administered antibiotics for prophylaxis against surgical wound infection. An in vivo study. J Bone Joint Surg Am. 2007;89:929–933.PubMedCrossRefGoogle Scholar
  62. 62.
    Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother. 2005;55:995–1002.PubMedCrossRefGoogle Scholar
  63. 63.
    Yun HC, Murray CK, Roop SA, Hospenthal DR, Gourdine E, Dooley DP. Bacteria recovered from patients admitted to a deployed U.S. military hospital in Baghdad, Iraq. Mil Med. 2006;171:821–825.PubMedGoogle Scholar
  64. 64.
    Ziglam H. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother. 2007;8:2279–2292.PubMedCrossRefGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons 2008

Authors and Affiliations

  • Jason H. Calhoun
    • 1
  • Clinton K. Murray
    • 2
  • M. M. Manring
    • 1
  1. 1.Department of Orthopaedic SurgeryUniversity of MissouriColumbiaUSA
  2. 2.Infectious Disease ServiceBrooke Army Medical CenterFort Sam HoustonUSA

Personalised recommendations